Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).

Abstract:

BACKGROUND:The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain pathology can be visualized in the cerebrospinal fluid (CSF) by protein profiling. It is clear that the field of Alzheimer's disease (AD) will benefit from an integration of algorithms including CSF concentrations of individual proteins, especially as an aid in clinical decision-making or to improve patient enrolment in clinical trials. The protein profiling approach requires standard operating procedures for collection and storage of CSF which must be easy to integrate into a routine clinical lab environment. Our study provides recommendations for analysis of neurogranin trunc P75, α-synuclein, and tau, in combination with the ratio of β-amyloid Aβ(1-42)/Aβ(1-40). METHODS:Protocols for CSF collection were compared with CSF derived from subjects with normal pressure hydrocephalus (n = 19). Variables included recipient type (collection, storage), tube volume, and addition of detergents at the time of collection. CSF biomarker analysis was performed with enzyme-linked immunosorbent assays (ELISAs). Data were analyzed with linear repeated measures and mixed effects models. RESULTS:Adsorption to recipients is lower for neurogranin trunc P75, α-synuclein, and tau (<10%), as compared to Aβ(1-42). For neurogranin trunc P75 and total tau, there is still an effect on analyte concentrations as a function of the tube volume. Protocol-related differences for Aβ(1-42) can be normalized at the (pre-)analytical level using the ratio Aβ(1-42)/Aβ(1-40), but not by using the ratio Aβ(1-42)/tau. The addition of detergent at the time of collection eliminates differences due to adsorption. CONCLUSIONS:Our study recommends the use of low protein binding tubes for quantification in CSF (without additives) of all relevant CSF biomarkers. Pre-analytical factors have less effect on α-synuclein, neurogranin trunc P75, and total tau, as compared to Aβ(1-42). The ratio of Aβ(1-42)/Aβ(1-40), but not Aβ(1-42)/tau, can be used to adjust for pre-analytical differences in analyte concentrations. Our study does not recommend the inclusion of detergents at the time of collection of CSF. The present results provide an experimental basis for new recommendations for parallel analysis of several proteins using one protocol for collection and storage of CSF.

journal_name

Alzheimers Res Ther

authors

Vanderstichele H,Demeyer L,Janelidze S,Coart E,Stoops E,Mauroo K,Herbst V,François C,Hansson O

doi

10.1186/s13195-017-0265-7

subject

Has Abstract

pub_date

2017-06-06 00:00:00

pages

40

issue

1

issn

1758-9193

pii

10.1186/s13195-017-0265-7

journal_volume

9

pub_type

杂志文章
  • Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome.

    abstract::The long-term consequences of repetitive head impacts have been described since the early 20th century. Terms such as punch drunk and dementia pugilistica were first used to describe the clinical syndromes experienced by boxers. A more generic designation, chronic traumatic encephalopathy (CTE), has been employed sinc...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-014-0068-z

    authors: Montenigro PH,Baugh CM,Daneshvar DH,Mez J,Budson AE,Au R,Katz DI,Cantu RC,Stern RA

    更新日期:2014-09-24 00:00:00

  • Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

    abstract:BACKGROUND:Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling. METHODS:We convened a ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-017-0261-y

    authors: Grill JD,Apostolova LG,Bullain S,Burns JM,Cox CG,Dick M,Hartley D,Kawas C,Kremen S,Lingler J,Lopez OL,Mapstone M,Pierce A,Rabinovici G,Roberts JS,Sajjadi SA,Teng E,Karlawish J

    更新日期:2017-05-04 00:00:00

  • Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.

    abstract:BACKGROUND:Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0477-0

    authors: Startin CM,Ashton NJ,Hamburg S,Hithersay R,Wiseman FK,Mok KY,Hardy J,Lleó A,Lovestone S,Parnetti L,Zetterberg H,Hye A,LonDownS Consortium.,Strydom A

    更新日期:2019-03-21 00:00:00

  • Increased Aβ42-α7-like nicotinic acetylcholine receptor complex level in lymphocytes is associated with apolipoprotein E4-driven Alzheimer's disease pathogenesis.

    abstract:BACKGROUND:The apolipoprotein E ε4 (APOE4) genotype is a prominent late-onset Alzheimer's disease (AD) risk factor. ApoE4 disrupts memory function in rodents and may contribute to both plaque and tangle formation. METHODS:Coimmunoprecipitation and Western blot detection were used to determine: 1) the effects of select...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0280-8

    authors: Wang HY,Trocmé-Thibierge C,Stucky A,Shah SM,Kvasic J,Khan A,Morain P,Guignot I,Bouguen E,Deschet K,Pueyo M,Mocaer E,Ousset PJ,Vellas B,Kiyasova V

    更新日期:2017-07-27 00:00:00

  • Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial.

    abstract:INTRODUCTION:The long-term efficacy and safety of donepezil 10 mg in patients with dementia with Lewy bodies (DLB) were investigated in a 52-week Phase 3 trial. METHODS:This 52-week study consisted of 16-week randomized placebo-controlled (RCT) and 36-week open-label extension phases. Of 142 DLB patients enrolled in t...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-014-0081-2

    authors: Mori E,Ikeda M,Nagai R,Matsuo K,Nakagawa M,Kosaka K

    更新日期:2015-02-03 00:00:00

  • Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals.

    abstract:BACKGROUND:Amyloid pathology, which is one of the characteristics of Alzheimer's disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ1-42 is evident in AD, and the CSF ratio Aβ42/Aβ40 has recentl...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00696-1

    authors: Lehmann S,Dumurgier J,Ayrignac X,Marelli C,Alcolea D,Ormaechea JF,Thouvenot E,Delaby C,Hirtz C,Vialaret J,Ginestet N,Bouaziz-Amar E,Laplanche JL,Labauge P,Paquet C,Lleo A,Gabelle A,Alzheimer’s Disease Neuroimaging Initi

    更新日期:2020-10-02 00:00:00

  • Study partners: essential collaborators in discovering treatments for Alzheimer's disease.

    abstract:BACKGROUND:Global leaders have set an ambitious goal of developing interventions to effectively treat or prevent Alzheimer's disease by 2025. CASE PRESENTATION:Achieving this goal will require clinical trials to test promising interventions, yet Alzheimer's researchers are confronting a clinical trial recruitment cris...

    journal_title:Alzheimer's research & therapy

    pub_type: 社论

    doi:10.1186/s13195-018-0425-4

    authors: Largent EA,Karlawish J,Grill JD

    更新日期:2018-09-27 00:00:00

  • Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease.

    abstract:INTRODUCTION:There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease (AD) assessed by repeated measures on serial tests of cognition and function. METHODS:Six hundre...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt7

    authors: Rountree SD,Chan W,Pavlik VN,Darby EJ,Siddiqui S,Doody RS

    更新日期:2009-10-21 00:00:00

  • A language-based sum score for the course and therapeutic intervention in primary progressive aphasia.

    abstract:BACKGROUND:With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far, volumetric brain changes have been proposed as clinical endpoints in the lit...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0345-3

    authors: Semler E,Anderl-Straub S,Uttner I,Diehl-Schmid J,Danek A,Einsiedler B,Fassbender K,Fliessbach K,Huppertz HJ,Jahn H,Kornhuber J,Landwehrmeyer B,Lauer M,Muche R,Prudlo J,Schneider A,Schroeter ML,Ludolph AC,Otto M,FTLD

    更新日期:2018-04-25 00:00:00

  • Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

    abstract:BACKGROUND:Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS:Here we describe the first clinical study with BAN2401. Safety and tolerability were...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1186/s13195-016-0181-2

    authors: Logovinsky V,Satlin A,Lai R,Swanson C,Kaplow J,Osswald G,Basun H,Lannfelt L

    更新日期:2016-04-06 00:00:00

  • The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

    abstract:INTRODUCTION:Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Both NPS have negative effects on cognitive performance and life expectancy. The current study aimed to investigate and compare monoaminergic etiologies betwe...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-014-0090-1

    authors: Vermeiren Y,Van Dam D,Aerts T,Engelborghs S,Martin JJ,De Deyn PP

    更新日期:2015-02-11 00:00:00

  • Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

    abstract::Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and molecular studies of autosomal-dominant Alzheimer's disease, highlighting the similarities and differences between...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt59

    authors: Bateman RJ,Aisen PS,De Strooper B,Fox NC,Lemere CA,Ringman JM,Salloway S,Sperling RA,Windisch M,Xiong C

    更新日期:2011-01-06 00:00:00

  • Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

    abstract::The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-019-0485-0

    authors: Hansson O,Lehmann S,Otto M,Zetterberg H,Lewczuk P

    更新日期:2019-04-22 00:00:00

  • Potential sources of interference on Abeta immunoassays in biological samples.

    abstract::Therapeutic products that depend on the use of an in vitro diagnostic biomarker test to confirm their effectiveness are increasingly being developed. Use of biomarkers is particularly meaningful in the context of selecting the patient population where the therapeutic treatment is believed to be efficacious (patient en...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt142

    authors: Vanderstichele H,Stoops E,Vanmechelen E,Jeromin A

    更新日期:2012-10-17 00:00:00

  • Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease.

    abstract:INTRODUCTION:There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testostero...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0107-4

    authors: Hall JR,Wiechmann AR,Cunningham RL,Johnson LA,Edwards M,Barber RC,Singh M,Winter S,O'Bryant SE,Texas Alzheimer’s Research and Care Consortium.

    更新日期:2015-05-01 00:00:00

  • The effects of different familial Alzheimer's disease mutations on APP processing in vivo.

    abstract:BACKGROUND:Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individu...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0234-1

    authors: Thordardottir S,Kinhult Ståhlbom A,Almkvist O,Thonberg H,Eriksdotter M,Zetterberg H,Blennow K,Graff C

    更新日期:2017-02-16 00:00:00

  • Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease.

    abstract:BACKGROUND:Neuroinflammation has gained increasing attention as a potential contributing factor in Alzheimer's disease (AD) pathology. A clinical cerebrospinal fluid biomarker capable of monitoring this process during the course of the disease has yet to emerge, chiefly owing to contradictory research findings. In this...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0353-3

    authors: Brosseron F,Traschütz A,Widmann CN,Kummer MP,Tacik P,Santarelli F,Jessen F,Heneka MT

    更新日期:2018-02-26 00:00:00

  • Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.

    abstract:INTRODUCTION:Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It reduces pathology in transgenic models of Alzheimer's disease (AD) and is a promising candidat...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt146

    authors: Ringman JM,Frautschy SA,Teng E,Begum AN,Bardens J,Beigi M,Gylys KH,Badmaev V,Heath DD,Apostolova LG,Porter V,Vanek Z,Marshall GA,Hellemann G,Sugar C,Masterman DL,Montine TJ,Cummings JL,Cole GM

    更新日期:2012-10-29 00:00:00

  • Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria.

    abstract:BACKGROUND:[18F]FDG-PET hypometabolism patterns are indicative of different neurodegenerative conditions, even from the earliest disease phase. This makes [18F]FDG-PET a valuable tool in the diagnostic workup of neurodegenerative diseases. The utility of [18F]FDG-PET in dementia with Lewy bodies (DLB) needs further val...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0473-4

    authors: Caminiti SP,Sala A,Iaccarino L,Beretta L,Pilotto A,Gianolli L,Iannaccone S,Magnani G,Padovani A,Ferini-Strambi L,Perani D

    更新日期:2019-02-23 00:00:00

  • In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

    abstract:BACKGROUND:Imaging agents capable of quantifying the brain's tau aggregates will allow a more precise staging of Alzheimer's disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0402-y

    authors: Pascoal TA,Shin M,Kang MS,Chamoun M,Chartrand D,Mathotaarachchi S,Bennacef I,Therriault J,Ng KP,Hopewell R,Bouhachi R,Hsiao HH,Benedet AL,Soucy JP,Massarweh G,Gauthier S,Rosa-Neto P

    更新日期:2018-07-31 00:00:00

  • Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.

    abstract:BACKGROUND:A growing number of pharmacological and nonpharmacological trials have been performed to test the efficacy of approved or experimental treatments in Alzheimer disease (AD) and mild cognitive impairment (MCI). In this context, functional magnetic resonance imaging (fMRI) may be a good candidate to detect brai...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-018-0347-1

    authors: Canu E,Sarasso E,Filippi M,Agosta F

    更新日期:2018-02-20 00:00:00

  • Subcortical hyperintensity volumetrics in Alzheimer's disease and normal elderly in the Sunnybrook Dementia Study: correlations with atrophy, executive function, mental processing speed, and verbal memory.

    abstract:INTRODUCTION:Subcortical hyperintensities (SHs) are radiological entities commonly observed on magnetic resonance imaging (MRI) of patients with Alzheimer's disease (AD) and normal elderly controls. Although the presence of SH is believed to indicate some form of subcortical vasculopathy, pathological heterogeneity, me...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt279

    authors: Ramirez J,McNeely AA,Scott CJ,Stuss DT,Black SE

    更新日期:2014-08-11 00:00:00

  • Utility of the Dependence Scale in dementia: validity, meaningfulness, and health economic considerations.

    abstract:BACKGROUND:The concept of dependence has been proposed as a unified representation of disease severity to quantify and stage disease progression in a manner more informative to patients, caregivers, and healthcare providers. METHODS:This paper provides a review of the Dependence Scale (DS) as a quantitative measure of...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-018-0414-7

    authors: Zhu CW,Bruinsma BG,Stern Y

    更新日期:2018-08-13 00:00:00

  • Systemic and central nervous system metabolic alterations in Alzheimer's disease.

    abstract:BACKGROUND:Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer's disease (AD) on both the systemic and central nervous system level. To study the extent and significance of these alterations in AD, quanti...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0551-7

    authors: van der Velpen V,Teav T,Gallart-Ayala H,Mehl F,Konz I,Clark C,Oikonomidi A,Peyratout G,Henry H,Delorenzi M,Ivanisevic J,Popp J

    更新日期:2019-11-28 00:00:00

  • APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain.

    abstract:BACKGROUND:The application of advanced sequencing technologies and improved mass-spectrometry platforms revealed significant changes in gene expression and lipids in Alzheimer's disease (AD) brain. The results so far have prompted further research using "multi-omics" approaches. These approaches become particularly rel...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0558-0

    authors: Lefterov I,Wolfe CM,Fitz NF,Nam KN,Letronne F,Biedrzycki RJ,Kofler J,Han X,Wang J,Schug J,Koldamova R

    更新日期:2019-12-30 00:00:00

  • Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?

    abstract::Symptomatic treatments for Alzheimer's disease should retain a place in the advanced stages of disease since their actions on these symptoms, even if not modifying the course of disease, are critical for improving patients' comfort and reducing the burden felt by caregivers, especially those facing behavioral disorder...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt228

    authors: Ousset PJ,Delrieu J,Vellas B

    更新日期:2013-12-11 00:00:00

  • Kidney function and dementia risk in community-dwelling older adults: the Shanghai Aging Study.

    abstract:BACKGROUND:Association between kidney dysfunction and dementia has been studied in western cohorts, but with inconsistent conclusions which may be due to the different measurements of kidney function. We aim to verify the hypothesis that lower levels of kidney function would be associated with increased risk of inciden...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00729-9

    authors: Wang M,Ding D,Zhao Q,Wu W,Xiao Z,Liang X,Luo J,Chen J

    更新日期:2021-01-11 00:00:00

  • The dynamics of monocytes and microglia in Alzheimer's disease.

    abstract::Alzheimer's disease (AD) is the most common neurodegenerative disorder affecting older people worldwide. It is a progressive disorder mainly characterized by the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles within the brain parenchyma. It is now well accepted that neuroinflammation constitutes an ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0125-2

    authors: Thériault P,ElAli A,Rivest S

    更新日期:2015-04-15 00:00:00

  • Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.

    abstract:INTRODUCTION:Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0143-0

    authors: Coutinho AM,Porto FH,Duran FL,Prando S,Ono CR,Feitosa EA,Spíndola L,de Oliveira MO,do Vale PH,Gomes HR,Nitrini R,Brucki SM,Buchpiguel CA

    更新日期:2015-09-15 00:00:00

  • Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization.

    abstract:BACKGROUND:Intracerebral inoculation of extracts from post-mortem human Alzheimer's disease brains into mice produces a prion-like spreading effect of amyloid-β. The differences observed between these extracts and the synthetic peptide, in terms of amyloid-β internalization and seed and cell-to-cell transmission of cyt...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0513-0

    authors: Pedrero-Prieto CM,Flores-Cuadrado A,Saiz-Sánchez D,Úbeda-Bañón I,Frontiñán-Rubio J,Alcaín FJ,Mateos-Hernández L,de la Fuente J,Durán-Prado M,Villar M,Martínez-Marcos A,Peinado JR

    更新日期:2019-06-29 00:00:00